{"id":"https://openalex.org/W2947072829","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.9070","title":"Time-to-treatment discontinuation (TTD) and real-world progression-free survival (rwPFS) as endpoints for comparative efficacy analysis between entrectinib trial and crizotinib real-world ROS1 fusion-positive (ROS1+) NSCLC patients.","display_name":"Time-to-treatment discontinuation (TTD) and real-world progression-free survival (rwPFS) as endpoints for comparative efficacy analysis between entrectinib trial and crizotinib real-world ROS1 fusion-positive (ROS1+) NSCLC patients.","publication_year":2019,"publication_date":"2019-05-20","ids":{"openalex":"https://openalex.org/W2947072829","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.9070","mag":"2947072829"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2019.37.15_suppl.9070","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.9070","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.9070","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5034705456","display_name":"Robert Charles Doebele","orcid":"https://orcid.org/0000-0001-6728-6857","observed_orcids":["https://orcid.org/0000-0001-6728-6857"]},"institutions":[{"id":"https://openalex.org/I921990950","display_name":"University of Colorado Denver","ror":"https://ror.org/02hh7en24","country_code":"US","type":"education","lineage":["https://openalex.org/I921990950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Charles Doebele","raw_affiliation_strings":["University of Colorado, Denver, CO;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Colorado, Denver, CO;","institution_ids":["https://openalex.org/I921990950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054828796","display_name":"Laura Mezquita P\u00e9rez","orcid":"https://orcid.org/0000-0002-1695-7494","observed_orcids":["https://orcid.org/0000-0002-1695-7494"]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Laura Perez","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd, Basel, Switzerland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd, Basel, Switzerland;","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073889590","display_name":"Huong Trinh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Huong Trinh","raw_affiliation_strings":["Genentech, South San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, South San Francisco, CA;","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080636105","display_name":"Michael Martinec","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Michael Martinec","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd, Basel, Switzerland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd, Basel, Switzerland;","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085188200","display_name":"Reynaldo Martina","orcid":"https://orcid.org/0000-0002-1925-820X","observed_orcids":["https://orcid.org/0000-0002-1925-820X"]},"institutions":[{"id":"https://openalex.org/I146655781","display_name":"University of Liverpool","ror":"https://ror.org/04xs57h96","country_code":"GB","type":"education","lineage":["https://openalex.org/I146655781"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Reynaldo Martina","raw_affiliation_strings":["University of Liverpool, Liverpool, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Liverpool, Liverpool, United Kingdom;","institution_ids":["https://openalex.org/I146655781"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113882339","display_name":"Todd Riehl","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Todd Riehl","raw_affiliation_strings":["Genentech, South San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, South San Francisco, CA;","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080991347","display_name":"Matthew Krebs","orcid":"https://orcid.org/0000-0001-7540-3064","observed_orcids":["https://orcid.org/0000-0001-7540-3064"]},"institutions":[{"id":"https://openalex.org/I28407311","display_name":"University of Manchester","ror":"https://ror.org/027m9bs27","country_code":"GB","type":"education","lineage":["https://openalex.org/I28407311"]},{"id":"https://openalex.org/I4210133995","display_name":"The Christie NHS Foundation Trust","ror":"https://ror.org/03v9efr22","country_code":"GB","type":"funder","lineage":["https://openalex.org/I4210133995"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Matthew Krebs","raw_affiliation_strings":["Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom;","institution_ids":["https://openalex.org/I28407311","https://openalex.org/I4210133995"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053128814","display_name":"Neal J. Meropol","orcid":"https://orcid.org/0000-0001-6353-7364","observed_orcids":["https://orcid.org/0000-0001-6353-7364"]},"institutions":[{"id":"https://openalex.org/I4210153546","display_name":"Flatiron Health (United States)","ror":"https://ror.org/0508h6p74","country_code":"US","type":"company","lineage":["https://openalex.org/I4210153546"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Neal J. Meropol","raw_affiliation_strings":["Flatiron Health, New York, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Flatiron Health, New York, NY;","institution_ids":["https://openalex.org/I4210153546"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025997705","display_name":"William Bruce Wong","orcid":"https://orcid.org/0000-0002-6054-278X","observed_orcids":["https://orcid.org/0000-0002-6054-278X"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William Bruce Wong","raw_affiliation_strings":["Genentech, South San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, South San Francisco, CA;","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5023655314","display_name":"Gracy Crane","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210113058","display_name":"Roche (United Kingdom)","ror":"https://ror.org/024tgbv41","country_code":"GB","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I4210113058"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Gracy Crane","raw_affiliation_strings":["F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom;","institution_ids":["https://openalex.org/I4210113058"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":8,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"37","issue":"15_suppl","first_page":"9070","last_page":"9070"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/entrectinib","display_name":"entrectinib","score":0.9789999723434448},{"id":"https://openalex.org/keywords/crizotinib","display_name":"crizotinib","score":1.0},{"id":"https://openalex.org/keywords/time-to-treatment-discontinuation","display_name":"time to treatment discontinuation","score":0.8519999980926514},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.953000009059906},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.7179999947547913},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.9269999861717224},{"id":"https://openalex.org/keywords/real-world-evidence","display_name":"real-world evidence","score":0.6800000071525574},{"id":"https://openalex.org/keywords/comparative-efficacy","display_name":"drug efficacy comparison","score":0.6129999756813049},{"id":"https://openalex.org/keywords/electronic-health-records","display_name":"electronic health records","score":0.6859999895095825},{"id":"https://openalex.org/keywords/propensity-score-matching","display_name":"propensity score matching","score":0.7139999866485596},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.9589999914169312},{"id":"https://openalex.org/keywords/brain-metastases","display_name":"brain metastases","score":0.7450000047683716},{"id":"https://openalex.org/keywords/smoking-status","display_name":"smoking status","score":0.6069999933242798},{"id":"https://openalex.org/keywords/prior-lines-of-therapy","display_name":"prior lines of therapy","score":0.8220000267028809}],"concepts":[{"id":"https://openalex.org/C2779422266","wikidata":"https://www.wikidata.org/wiki/Q5186964","display_name":"Crizotinib","level":4,"score":0.9558819532394409},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8534427881240845},{"id":"https://openalex.org/C2775999482","wikidata":"https://www.wikidata.org/wiki/Q18031208","display_name":"ROS1","level":4,"score":0.7770623564720154},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.645104169845581},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6408452987670898},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.5723264813423157},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5646007061004639},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.5134221315383911},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5044373273849487},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.4972842037677765},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4783848524093628},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4232247471809387},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4145898222923279},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.38898539543151855},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.17255520820617676},{"id":"https://openalex.org/C2781182431","wikidata":"https://www.wikidata.org/wiki/Q356033","display_name":"Adenocarcinoma","level":3,"score":0.13666966557502747},{"id":"https://openalex.org/C2776232967","wikidata":"https://www.wikidata.org/wiki/Q6743514","display_name":"Malignant pleural effusion","level":3,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2019.37.15_suppl.9070","doi":"https://doi.org/10.1200/jco.2019.37.15_suppl.9070","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.15_suppl.9070","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9789000153541565,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.5199999809265137,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2981403738","https://openalex.org/W3193977597","https://openalex.org/W3138084973","https://openalex.org/W4214916868","https://openalex.org/W4404214345","https://openalex.org/W4281751296","https://openalex.org/W4292457570","https://openalex.org/W4393092878","https://openalex.org/W4225123144","https://openalex.org/W3088110133"],"abstract_inverted_index":{"9070":[0],"Background:":[1],"Entrectinib":[2,109,248],"is":[3,41,296],"an":[4],"oral":[5],"tyrosine":[6],"kinase":[7],"inhibitor":[8],"for":[9],"ROS1+":[10,31,50,78,179,257],"NSCLC.":[11],"Three":[12],"phase":[13],"1/2":[14],"single-arm":[15],"studies":[16],"showed":[17],"entrectinib":[18,67,175,206,221],"efficacy":[19],"in":[20,37,70,93,256,278],"this":[21],"population":[22],"(Doebele":[23],"WCLC":[24],"2018).":[25],"Due":[26],"to":[27,58,66,84,115,203],"the":[28,61,94,117],"rarity":[29],"of":[30,49,64,166,283],"pts":[32,52,75,104,259],"generating":[33],"direct":[34],"comparative":[35],"evidence":[36,274],"prospective":[38],"randomized":[39],"trials":[40,277],"difficult.":[42],"We":[43,172],"identified":[44,89],"a":[45,261],"retrospective":[46],"real-world":[47,263,270],"cohort":[48,119],"NSCLC":[51,79,180,258],"from":[53,105,128,199,269,275],"electronic":[54],"health":[55],"records":[56],"(EHR),":[57],"compare":[59],"crizotinib,":[60,191],"current":[62],"standard":[63],"care,":[65],"as":[68,120,122],"reported":[69],"clinical":[71,276],"trials.":[72],"Methods:":[73],"Crizotinib-treated":[74],"with":[76,90,220,232,251],"advanced":[77],"diagnosed":[80],"1":[81],"Jan":[82],"2011":[83],"30":[85],"Jun":[86],"2018,":[87],"were":[88,113,137,168,241],"technology-enabled":[91],"abstraction":[92],"Flatiron":[95],"Health":[96],"EHR-derived":[97],"database":[98],"(":[99],">":[100],"2.1":[101],"million":[102],"cancer":[103],"US":[106],"oncology":[107],"practice).":[108],"trial":[110,204],"inclusion/exclusion":[111],"criteria":[112],"applied":[114],"match":[116],"crizotinib":[118,178,200,211,233,264],"closely":[121],"possible.":[123],"Primary":[124],"endpoint:":[125],"TTD,":[126],"adapted":[127],"Gong":[129],"(ASCO":[130],"2018);":[131],"rwPFS":[132,198],"(physician/scan":[133],"report)":[134],"and":[135,146,163,176,254,294],"OS":[136,219,231],"secondary":[138],"outcomes.":[139],"Time-to-event":[140],"analyses":[141],"used":[142],"Kaplan-Meier":[143],"survival":[144],"curves":[145],"Cox":[147],"proportional":[148],"hazard":[149],"models":[150],"on":[151],"propensity":[152],"score":[153],"weighted":[154,183,229],"populations;":[155],"age,":[156],"gender,":[157],"race/ethnicity,":[158],"smoking":[159],"status,":[160],"brain":[161],"metastasis":[162],"previous":[164],"lines":[165],"therapy":[167],"prognostic":[169],"factors.":[170],"Results:":[171],"analyzed":[173],"53":[174],"69":[177],"pts.":[181],"Median":[182,218],"TTD:":[184],"entrectinib,":[185],"14.6":[186],"mo":[187,193,236],"(95%":[188,194,237],"CI:":[189,195,216,238],"8.3\u201323.8);":[190],"8.8":[192],"8.2\u20139.9).":[196],"When":[197],"was":[201,222,234,249],"compared":[202],"PFS,":[205],"had":[207],"longer":[208,252],"PFS":[209,255],"vs":[210,260],"(weighted":[212],"HR:":[213],"0.44;":[214],"95%":[215],"0.27\u20130.74).":[217],"not":[223,297],"reached":[224],"(median":[225],"follow-up:":[226],"15.5":[227],"mo);":[228],"median":[230],"18.5":[235],"15.1\u201319.9).":[239],"Findings":[240],"consistent":[242],"across":[243],"multiple":[244],"sensitivity":[245],"analyses.":[246],"Conclusions:":[247],"associated":[250],"TTD":[253],"matched":[262],"population.":[265],"Control":[266],"populations":[267],"derived":[268],"cohorts":[271],"can":[272],"supplement":[273],"settings":[279],"where":[280,288],"new":[281],"standards":[282],"care":[284],"are":[285,292],"needed,":[286],"but":[287],"only":[289],"limited":[290],"data":[291],"available":[293],"randomization":[295],"feasible.":[298]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2019-06-07T00:00:00"}